Cyrus Biotechnology

Executive Summary

Cyrus Biotechnology is a Seattle-based, computationally-driven biotech company founded in 2016 that leverages AI-powered protein design and drug discovery platforms to engineer optimized biologics from naturally occurring proteins. The company's core technology, rooted in advanced computational modeling and machine learning, enables the rapid design of superior therapeutic candidates with enhanced stability, specificity, and manufacturability. Cyrus focuses primarily on severe autoimmune diseases, aiming to develop novel biologics that address significant unmet medical needs in indications such as lupus, rheumatoid arthritis, and inflammatory bowel disease. As a private company, Cyrus has operated largely under the radar, with limited public disclosures regarding its pipeline or funding. However, its AI-driven approach positions it within a rapidly growing sector of computational drug discovery, attracting interest from both venture capital and large pharma partners seeking innovative biologics. The company's differentiation lies in its ability to computationally design proteins that can evade the immune system, improve half-life, and target challenging epitopes. While still early-stage, Cyrus has the potential to become a key player in the next generation of biologic therapeutics, contingent on successful validation of its platform and progression of its lead candidates into clinical development.

Upcoming Catalysts (preview)

• Q2 2027Pharmaceutical partnership for autoimmune drug discovery program40% success
• Q4 2026Series B or C funding round led by top-tier life sciences VCs60% success
• Q1 2027Announcement of IND-enabling studies for lead biologic candidate35% success